Oryzon Genomics S.A. (BME:ORY)
Spain
· Delayed Price · Currency is EUR 3.140
-0.080 (-2.48%)
At close: Feb 27, 2026
Oryzon Genomics Revenue
Revenue (ttm)
$7.36M
Revenue Growth
-45.45%
P/S Ratio
33.65
Revenue / Employee
$156.57K
Employees
47
Market Cap
247.60M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 7.62M | -8.07M | -51.43% |
| Dec 31, 2023 | 15.69M | -1.09M | -6.50% |
| Dec 31, 2022 | 16.78M | 4.70M | 38.97% |
| Dec 31, 2021 | 12.07M | 425.74K | 3.66% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.52B |
| Laboratorios Farmaceuticos Rovi | 724.20M |
| Almirall | 1.11B |
| Faes Farma | 571.12M |
| Pharma Mar | 179.28M |
| Clínica Baviera | 296.76M |
| Prim, S.A. | 240.68M |
| Atrys Health | 226.24M |
Oryzon Genomics News
- 5 days ago - ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia - Benzinga